Exelixis | EXEL - Market Capitalization


Exelixis reported $12.53B in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Agios Pharmaceuticals USD 1.59B 745M Dec/2025
Akebia Therapeutics USD 427M 297M Dec/2025
Amgen USD 176.25B 24.32B Dec/2025
AstraZeneca USD 288.15B 55.08B Dec/2025
Bayer EUR 36.36B 9.13B Dec/2025
BioMarin Pharmaceutical USD 11.42B 1.02B Dec/2025
Bristol-Myers Squibb USD 109.81B 18.01B Dec/2025
Cytokinetics USD 7.77B 1.19B Dec/2025
Eisai JPY 1.31T 140.95B Dec/2025
Eli Lilly USD 1.02T 293.84B Dec/2025
Esperion Therapeutics USD 885M 351M Dec/2025
Exelixis USD 11.75B 959M Dec/2025
Genmab DKK 20.48B 1.02B Dec/2025
Glaxosmithkline GBP 99.93B 13.05B Dec/2025
Incyte USD 19.39B 2.83B Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
MacroGenics USD 102M 4M Dec/2025
Merck USD 261.26B 51.62B Dec/2025
Nektar Therapeutics USD 14.34B 13.48B Apr/2026
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Novartis USD 292.21B 26.55B Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
Sanofi EUR 117.34B 2.45B Dec/2025
Takeda JPY 7.64T 774.9B Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Xencor USD 1.09B 256M Dec/2025